The U.S. Drug Enforcement Agency has given the green light to a clinical study of smoked marijuana’s effectiveness for treating Post Traumatic Stress Disorder in veterans, according to the Multidisciplinary Association for Psychedelic Studies.
The California-based MAPS is sponsoring the research, which will be funded by a $2.156 million grant from the Colorado Department of Public Health and Environment.
“The DEA’s approval marks the first time a clinical trial intended to develop smoked botanical marijuana into a legal prescription drug has received full approval from U.S. regulatory agencies, including the DEA and the Food and Drug Administration,” MAPS said in a press release.
Seventy-six U.S. veterans with PTSD will participate in the study.
“We have been working towards approval since we opened the Investigational New Drug Application with the FDA in 2010,” Amy Emerson, Executive Director and Director of Clinical Research for the MAPS Public Benefit Corporation, said. “We are thrilled to see this study overcome the hurdles of approval so we can begin gathering the data. This study is a critical step in moving our botanical drug development program forward at the federal level to gather information on the dosing, risks, and benefits of smoked marijuana for PTSD symptoms.”